



Tanvex BioPharma Attends ASHP

Dec. 06, 2018

Tanvex BioPharma, Inc. (TWSE: 6541) is expecting to commercialize their first biosimilar product (TX01) in 2019. As part of preparation, Tanvex BioPharma attended the ASHP Midyear Clinical Meeting and Exhibition in Anaheim, CA, USA from December 02 thru 06, 2018. Tanvex BioPharma, Inc. had its first official booth, initiating our marketing awareness of the organization, manufacturing capabilities and its immediate pipeline of products. The sales and marketing team met with major wholesalers, key hospital administrators and Group Purchasing Organizations (GPO's).

ASHP (American Society of Hospital Pharmacists) is one of the largest events that encompasses many pharmacy professionals in the world. Attended by more than 25,000 pharmacy professionals from all over the globe, the Midyear Clinical Meeting provides valuable opportunities for professional development, networking, enhancing practice skills and staying current with the latest products and innovations. Tanvex's commercial attendance allowed them to introduce the company mission of "Driving greater good through safe, effective and affordable biopharmaceuticals such as biosimilars".



About Tanvex

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.